BRITE-SVG

BRITE-SVG

Beta Radiation to Reduce In-Stent Restenosis of Saphenous Vein Graft. A small trial that assessed the RDX system in reducing/preventing in-stent restenosis for saphenous vein bypass grafts, which reported good results with further studies planned.

Logistics
50 patients at 6 international centres, treating de novo and in-stent SVG blockages up to 45 mm in length in graft diameters of 3.0 mm to 4.5 mmg.
References in periodicals archive ?
In addition, the enrollment and follow-up evaluation of the patients in the RAPID (Radiation After PTA Is Done) and BRITE-SVG (Beta Radiation to Reduce In-Stent Restenosis for Saphenous Vein Bypass Grafts) Studies are on schedule.
The BRITE-SVG Study is a Phase I safety study designed to evaluate the safety of the RDX System for the treatment of de novo lesions and in-stent restenosis in saphenous vein bypass grafts ("SVG").
clinical studies, BRITE II and BRITE-SVG (Beta Radiation to Reduce In-Stent Restenosis for Saphenous Vein Bypass Grafts).
In addition, Thiel is expected to discuss key corporate milestones including the status of the company's BRITE II and BRITE-SVG (Beta Radiation to Reduce In-Stent Restenosis for Saphenous Vein Bypass Grafts) Clinical Studies; the CE-Mark approval process; initiation of human clinical studies in Japan and the upcoming human clinical studies using the RDX Technology in the peripheral vasculature.
Food and Drug Administration ("FDA") approval to use new catheter designs in the BRITE II (Beta Radiation to Reduce In-Stent Restenosis) and BRITE-SVG (Beta Radiation to Reduce In-Stent Restenosis for Saphenous Vein Bypass Grafts) Clinical Studies.
studies for the RDX(TM) Radiation Delivery Catheter, including the final phase BRITE II and BRITE-SVG Study.
Nasdaq:RADX) Tuesday announced that the first patient has been enrolled in the BRITE-SVG (Beta Radiation to Reduce In-Stent Restenosis for Saphenous Vein Bypass Grafts) Clinical Study.
To the company's knowledge, the BRITE-SVG Study is the only current study underway in the United States to prove the clinical value of vascular brachytherapy in saphenous vein bypass graft patients.
The BRITE-SVG Study is a Phase I safety study designed to evaluate the safety of its RDX(TM) Coronary Radiation Delivery System for the treatment of de novo (not previously treated) lesions and in-stent restenosis in saphenous vein bypass grafts ("SVG").
The BRITE-SVG will enroll 50 patients at 6 centers worldwide treating de novo (not previously treated) and in-stent SVG blockages up to 45mm in length in graft diameters of 3.
Food and Drug Administration ("FDA") approval to commence its BRITE-SVG (Beta Radiation to Reduce In-Stent Restenosis for Saphenous Vein Bypass Grafts) Clinical Study designed to evaluate the safety of its RDX(TM) Coronary Radiation Delivery System for the treatment of de novo (not previously treated) lesions and in-stent restenosis in saphenous vein bypass grafts ("SVG").
The new trial, called the BRITE-SVG (Saphenous Vein Graft), will commence upon FDA approval of the IDE application.